Rivus Pharmaceuticals

Rivus Pharmaceuticals is focused on advancing cardiometabolic health by developing new oral medicines from its proprietary development platform. Its lead therapy HU6 is a potential best-in-class oral MASH therapy, advancing in the ongoing AMPLIFY Phase 2 trial for MASH. The pipeline also includes RV-8451, a highly-differentiated oral GLP-1, in IND-enabling studies for obesity.

Rivus Pharmaceuticals is a company in Charlottesville, United States. It is focused on advancing cardiometabolic health by developing new oral medicines from its proprietary development platform. Its lead therapy HU6 is a potential best-in-class oral MASH therapy, advancing in the ongoing AMPLIFY Phase 2 trial for MASH. The pipeline also includes RV-8451, a highly-differentiated oral GLP-1, in IND-enabling studies for obesity.

• HU6

  Potential best-in-class oral MASH therapy, advancing in the ongoing AMPLIFY Phase 2 trial for MASH.

• RV-8451

  Highly-differentiated oral GLP-1, in IND-enabling studies for obesity.

• 2021.07.20

  Reported2021.07.20

  Rivus Pharmaceuticals completes $35 million Series A financing[4]Rivus Pharmaceuticals完成3,500万美元A轮融资prnewswire.com

  Rivus Pharmaceuticals announced that it had completed a $35 million Series A financing. The round was co-led by Longitude Capital and Medicxi, with RxCapital also participating.

Read more

1. 1Rivus Pharmaceuticalsrivuspharma.com
2. 2About | Management | Board of Director | Investors | Rivus Pharmaceuticalsrivuspharma.com
3. 3Rivus Pharmaceuticals, Inc. (United States)wikidata.org
4. 4Rivus Pharmaceuticals完成3,500万美元A轮融资prnewswire.com